The company intends to use the funds to advance its lead candidate, PK10571, into Phase 1 clinical trials in patients with pulmonary arterial hypertension (PAH).
Led by Dr. Lawrence S. Zisman, CEO, Pulmokine develops PK10571, an inhibitor of the PDGF receptor kinase, designed to reduce and potentially reverse the pulmonary cell proliferation that leads to PAH. Preclinical studies have shown that treatment with PK10571 reduces pulmonary artery systolic pressure, a key measure of PAH
The company expects to submit an Investigational New Drug application to the U.S. Food and Drug Administration in the fourth quarter of 2015, and commence Phase 1 trials
following the clearance of that application.
The development of PK10571 is also funded by a phase II SBIR grant from the NIH, and a Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health.